LEAP-006 was a randomized, placebo-controlled phase 3 trial evaluating pembrolizumab with pemetrexed and platinum-containing chemotherapy with or without lenvatinib as first-line treatment in metastatic NSCLC without existing EGFR-, ALK- or ROS1 genetic aberration. Here, EGFR is linked to non-small cell lung carcinoma.